This phase 1 clinical trial examines the escalation and safety of humanized anti-GD2 antibody doses in combination with granulocyte-macrophage colony-stimulating factor for treating patients with high-risk neuroblastoma.
https://ift.tt/2QKqO6S
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
http://bit.ly/2SylJiJ
-
Publication date: Available online 22 March 2017 Source: Medical Journal Armed Forces India Author(s): S.C. Shaw, M.S. Vinod, Amit Devgan ...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου